De-Risking Innovation: Turning Global Biotech Programs into Institutional-Grade Assets
Overview
This forum convenes a curated group of investors, founders, and development leaders around one central question:
👉 What actually makes a biotech program investable at an institutional level?
While scientific breakthroughs drive the industry, capital decisions are shaped by:
Risk reduction
Structural design
Regulatory and manufacturing readiness
This is a closed-door, decision-focused session — not a pitch event or scientific symposium — designed to explore how biotech assets become partnerable, scalable, and execution-ready.
Program
🧭 Framing Brief — The De-Risking Map
A concise framework on how institutional investors evaluate early-stage programs:
Key risk categories: scientific, regulatory, CMC, execution
What constitutes meaningful de-risking at the pre-IND stage
How development design influences investability
🎤 Panel 1 — Capital as a De-Risking Engine
Focus: Pre-IND → IND transition
How investors, founders, and CRO partners work together to reduce risk in practice:
What investors actually underwrite
Which data and milestones reduce uncertainty
How CROs shape IND-enabling strategy
Common gaps that block funding
👉 What needs to be de-risked for a program to become investable?
🧠 Strategic Briefing — Manufacturing & Structural Readiness
Focus: CMC as a hidden driver of valuation
Manufacturing strategy as a signal in diligence
Data design for regulatory flexibility
Structural decisions that impact partnership outcomes
🌍 Panel 2 — Global Strategy as a De-Risking Lever
Focus: Cross-border development strategy
Leveraging China, Australia, and ex-US pathways
Balancing speed, cost, and credibility
How global data is evaluated by investors and regulators
Sequencing strategies for earlier value inflection
👉 How can global strategy increase—not weaken—institutional confidence?
Observer Access (Online)
A limited number of online observer passes are available for those unable to attend in person. This includes live viewing access to the full program, offering visibility into the discussions across both panels. While in-room participation is reserved for onsite attendees, this provides a window into how experienced stakeholders evaluate and de-risk biotech assets in practice.
🚀 Curated Asset Review — Institutional Readiness in Practice
Depending on session flow and participant mix, the program may include a structured asset review segment, where selected companies present for focused discussion:
Key risks addressed
Remaining uncertainties
Next value inflection point
👉 Designed to surface decision-critical insights, not presentations.
Who Should Attend
Curated participation from:
Investors
Pharma / BD leaders
Experienced founders
Development & regulatory experts
Positioning
A high-signal, invitation-only forum for those operating at the intersection of:
👉 Innovation × Capital × Execution
TopContenders Bio / Life Sciences Series
Principal Sponsor: Nona Biosciences
Hosted at LabShares
Supporting Partners:
⚠️ Disclaimer
Photos and video recordings may be taken and used for promotional purposes
Program topics, speakers, and schedule are subject to change
This event does not constitute investment advice or solicitation
By attending, you consent to sharing registration information with organizers and sponsors for event-related communication